qfx

The final accounting for the year 2025 revealed a modest increase in fourth-quarter revenue, reaching $12.5 billion. A figure, however, that obscures a deeper diminution. Net income, calculated according to the accepted, yet often misleading, principles of accounting, suffered a decline of nearly twenty-four percent, falling to $2.6 billion. This is not an isolated incident, but a symptom of a longer, more insidious malady – the erosion of established pharmaceutical dominance.

Last week, in the austere halls of Minneapolis, Fiddelke unveiled not merely a “turnaround strategy,” but a confession. A reckoning with years of misguided ambition. The stock, predictably, offered a fleeting nod of approval, a momentary reprieve from the prevailing pessimism. But beneath the surface, a more profound drama unfolds. This is not a plan born of naive optimism, but a desperate attempt to salvage something from the wreckage of a flawed vision.

They announced a collaboration with Microsoft, a grand gesture intended to impress the markets. A partnership, they proclaimed, to weave artificial intelligence into the very sinews of their robotic systems. It was a siren song to investors, a fleeting dream of exponential growth. The shares, predictably, surged. But dreams, as any worker will tell you, rarely survive contact with reality.

Mueller Industries, a manufacturer of components – metal and plastic, predominantly – for systems of heating, ventilation, and the chilling of spaces, published its final report for the year 2025. The report, a document of meticulous detail and, ultimately, limited consequence, arrived at the beginning of February, and with it, a renewed sense of the inescapable cycle of reporting and re-evaluation.

Teradyne’s fourth quarter, concluding the year of 2025, presented a picture of robust health. Revenue and profitability, those twin engines of any enterprise, grew at a pace that suggested not a fleeting surge, but a sustained momentum. The total revenue reached $1.08 billion, a considerable sum, and a testament to the demand for its specialized instruments. The semiconductor diagnostics division, naturally, led the way, contributing $883 million. Product and robotics testing, while smaller in scale at $110 million and $89 million respectively, nonetheless demonstrated healthy growth, suggesting a diversification that is always a welcome sign.

Look, if you’re going to pick a horse, pick Secretariat. Don’t try to find some artisanal, free-range tech startup that’s been hand-crafted in a garage. Just buy Nvidia (NVDA 2.94%). It’s the big, shiny one. They make the graphics cards that make the AI happen. It’s like they own the plumbing for the entire digital brain. And honestly, it’s a good business model. Everyone needs plumbing. They’ve built a moat around their CUDA software, which is basically the secret sauce that makes everything run. And people are throwing money at AI infrastructure like it’s going out of style. Which, let’s be real, it probably is. But hey, ride the wave while it lasts.

But which, if one were forced to choose – and the market, naturally, forces one to choose – presents the more… agreeable proposition? Let’s have a little dig, shall we?

But let’s be clear. Nobody possesses a crystal ball, and predictin’ the market is a fool’s errand – though plenty of folks try, and profit handsomely from the attempts, I might add. Still, a prudent man prepares for a rainy day, and a wise investor doesn’t wait for the storm to brew before buildin’ a shelter. I’ve been lookin’ at a few exchange-traded funds – ETFs, they call ’em – that seem likely to hold up well, even if the market decides to take a tumble. These aren’t get-rich-quick schemes, mind you, but solid investments for the long haul.